FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285732910> ?p ?o ?g. }

• W4285732910 endingPage "1134" @default.
• W4285732910 startingPage "1134" @default.
• W4285732910 abstract "Plasmodium falciparum circumsporozoite protein (PfCSP) and Pfs25 are leading candidates for the development of pre-erythrocytic and transmission-blocking vaccines (TBV), respectively. Although considerable progress has been made in developing PfCSP- and Pfs25-based vaccines, neither have elicited complete protection or transmission blocking in clinical trials. The combination of antigens targeting various life stages is an alternative strategy to develop a more efficacious malaria vaccine. In this study, female and male mice were immunized with DNA plasmids encoding PfCSP and Pfs25, administered alone or in combination via intramuscular in vivo electroporation (EP). Antigen-specific antibodies were analyzed for antibody titers, avidity and isotype by ELISA. Immune protection against sporozoite challenge, using transgenic P. berghei expressing PfCSP and a GFP-luciferase fusion protein (PbPfCSP-GFP/Luc), was assessed by in vivo bioluminescence imaging and blood-stage parasite growth. Transmission reducing activity (TRA) was evaluated in standard membrane feeding assays (SMFA). High levels of PfCSP- and Pfs25-specific antibodies were induced in mice immunized with either DNA vaccine alone or in combination. No difference in antibody titer and avidity was observed for both PfCSP and Pfs25 between the single DNA and combined DNA immunization groups. When challenged by PbPfCSP-GFP/Luc sporozoites, mice immunized with PfCSP alone or combined with Pfs25 revealed significantly reduced liver-stage parasite loads as compared to mice immunized with Pfs25, used as a control. Furthermore, parasite liver loads were negatively correlated with PfCSP-specific antibody levels. When evaluating TRA, we found that immunization with Pfs25 alone or in combination with PfCSP elicited comparable significant transmission reduction. Our studies reveal that the combination of PfCSP and Pfs25 DNAs into a vaccine delivered by in vivo EP in mice does not compromise immunogenicity, infection protection and transmission reduction when compared to each DNA vaccine individually, and provide support for further evaluation of this DNA combination vaccine approach in larger animals and clinical trials." @default.
• W4285732910 created "2022-07-18" @default.
• W4285732910 creator A5000234141 @default.
• W4285732910 creator A5025082404 @default.
• W4285732910 creator A5026524903 @default.
• W4285732910 creator A5030612436 @default.
• W4285732910 creator A5034205739 @default.
• W4285732910 creator A5038638158 @default.
• W4285732910 creator A5055673972 @default.
• W4285732910 creator A5067232039 @default.
• W4285732910 creator A5074698824 @default.
• W4285732910 creator A5080784518 @default.
• W4285732910 date "2022-07-16" @default.
• W4285732910 modified "2023-09-30" @default.
• W4285732910 title "Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission" @default.
• W4285732910 cites W1513221000 @default.
• W4285732910 cites W1998160882 @default.
• W4285732910 cites W1999298446 @default.
• W4285732910 cites W2007098121 @default.
• W4285732910 cites W2016696697 @default.
• W4285732910 cites W2027088291 @default.
• W4285732910 cites W2050608587 @default.
• W4285732910 cites W2053801470 @default.
• W4285732910 cites W2060732719 @default.
• W4285732910 cites W2060917021 @default.
• W4285732910 cites W2065818546 @default.
• W4285732910 cites W2065849927 @default.
• W4285732910 cites W2072162271 @default.
• W4285732910 cites W2075819256 @default.
• W4285732910 cites W2121300211 @default.
• W4285732910 cites W2132042285 @default.
• W4285732910 cites W2132788867 @default.
• W4285732910 cites W2133294119 @default.
• W4285732910 cites W2136797050 @default.
• W4285732910 cites W2141913755 @default.
• W4285732910 cites W2185434840 @default.
• W4285732910 cites W2289261122 @default.
• W4285732910 cites W2413417242 @default.
• W4285732910 cites W2526349538 @default.
• W4285732910 cites W2557596101 @default.
• W4285732910 cites W2604574031 @default.
• W4285732910 cites W2760237399 @default.
• W4285732910 cites W2767717559 @default.
• W4285732910 cites W2791741332 @default.
• W4285732910 cites W2803463081 @default.
• W4285732910 cites W2809277835 @default.
• W4285732910 cites W2825109425 @default.
• W4285732910 cites W2883669154 @default.
• W4285732910 cites W2885422062 @default.
• W4285732910 cites W2903491984 @default.
• W4285732910 cites W2933655368 @default.
• W4285732910 cites W2942187201 @default.
• W4285732910 cites W2969640204 @default.
• W4285732910 cites W2976620503 @default.
• W4285732910 cites W2995069504 @default.
• W4285732910 cites W3014901343 @default.
• W4285732910 cites W3034248695 @default.
• W4285732910 cites W3038684426 @default.
• W4285732910 cites W3125450116 @default.
• W4285732910 cites W3173457545 @default.
• W4285732910 cites W3193427089 @default.
• W4285732910 cites W3205323734 @default.
• W4285732910 cites W4200269625 @default.
• W4285732910 cites W4254848468 @default.
• W4285732910 doi "https://doi.org/10.3390/vaccines10071134" @default.
• W4285732910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35891298" @default.
• W4285732910 hasPublicationYear "2022" @default.
• W4285732910 type Work @default.
• W4285732910 citedByCount "2" @default.
• W4285732910 countsByYear W42857329102022 @default.
• W4285732910 countsByYear W42857329102023 @default.
• W4285732910 crossrefType "journal-article" @default.
• W4285732910 hasAuthorship W4285732910A5000234141 @default.
• W4285732910 hasAuthorship W4285732910A5025082404 @default.
• W4285732910 hasAuthorship W4285732910A5026524903 @default.
• W4285732910 hasAuthorship W4285732910A5030612436 @default.
• W4285732910 hasAuthorship W4285732910A5034205739 @default.
• W4285732910 hasAuthorship W4285732910A5038638158 @default.
• W4285732910 hasAuthorship W4285732910A5055673972 @default.
• W4285732910 hasAuthorship W4285732910A5067232039 @default.
• W4285732910 hasAuthorship W4285732910A5074698824 @default.
• W4285732910 hasAuthorship W4285732910A5080784518 @default.
• W4285732910 hasBestOaLocation W42857329101 @default.
• W4285732910 hasConcept C104317684 @default.
• W4285732910 hasConcept C147483822 @default.
• W4285732910 hasConcept C159047783 @default.
• W4285732910 hasConcept C159654299 @default.
• W4285732910 hasConcept C167508917 @default.
• W4285732910 hasConcept C179223381 @default.
• W4285732910 hasConcept C186852380 @default.
• W4285732910 hasConcept C203014093 @default.
• W4285732910 hasConcept C22889606 @default.
• W4285732910 hasConcept C2778048844 @default.
• W4285732910 hasConcept C2778371730 @default.
• W4285732910 hasConcept C2780801004 @default.
• W4285732910 hasConcept C2780868878 @default.
• W4285732910 hasConcept C2781034427 @default.
• W4285732910 hasConcept C2781074509 @default.

• next